Evaluation of imatinib mesylate as a possible treatment for nephrogenic systemic fibrosis in a rat model

Magnetic Resonance Imaging

Volumn 31, Issue 1, 2013, Pages 139-144

  Hope, Thomas A ^a   LeBoit, Philip E ^a   High, Whitney A ^b   Fu, Yanjun ^a   Brasch, Robert C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Imatinib; Nephrogenic systemic fibrosis; Treatment

Indexed keywords

GADODIAMIDE; IMATINIB; IRON DEXTRAN; METAL; RECOMBINANT ERYTHROPOIETIN; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFICACY; HISTOPATHOLOGY; MALE; MASS SPECTROMETRY; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; PRIORITY JOURNAL; RAT; SKIN CALCIFICATION; SKIN CELL; SKIN FIBROSIS;

ANIMALS; BENZAMIDES; CONTRAST MEDIA; GADOLINIUM DTPA; MALE; NEPHROGENIC FIBROSING DERMOPATHY; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RATS; RATS, WISTAR; TREATMENT OUTCOME;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 84870323256     PISSN: 0730725X     EISSN: 18735894     Source Type: Journal    
DOI: 10.1016/j.mri.2012.06.027     Document Type: Article

References (29)

1. Cowper S.E., Su L.D., Bhawan J., Robin H.S., LeBoit P.E. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001, 23(5):383-393.
2. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant 2006, 21(4):1104-1108.
3. Marckmann P., Skov L., Rossen K., Dupont A., Damholt M.B., Heaf J.G., et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006, 17(9):2359-2362.
4. Buchdunger E., O'Reilly T., Wood J. Pharmacology of imatinib (STI571). Eur J Cancer 2002, 38(Suppl 5):S28-S36.
5. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344(14):1031-1037.
6. Aono Y., Nishioka Y., Inayama M., Ugai M., Kishi J., Uehara H., et al. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 2005, 171(11):1279-1285.
7. Azuma M., Nishioka Y., Aono Y., Inayama M., Makino H., Kishi J., et al. Role of alpha1-acid glycoprotein in therapeutic antifibrotic effects of imatinib with macrolides in mice. Am J Respir Crit Care Med 2007, 176(12):1243-1250.
8. Baroni S.S., Santillo M., Bevilacqua F., Luchetti M., Spadoni T., Mancini M., et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006, 354(25):2667-2676.
9. Distler J.H., Jungel A., Huber L.C., Schulze-Horsel U., Zwerina J., Gay R.E., et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007, 56(1):311-322.
10. Kay J., High W.A. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum 2008, 58(8):2543-2548.
11. Chandran S., Petersen J., Jacobs C., Fiorentino D., Doeden K., Lafayette R.A. Imatinib in the treatment of nephrogenic systemic fibrosis. Am J Kidney Dis 2009, 53(1):129-132.
12. Elmholdt T.R., Pedersen M., Jorgensen B., Ramsing M., Olesen A.B. Positive effect of low-dose imatinib mesylate in a patient with nephrogenic systemic fibrosis. Acta Derm Venereol 2011, 91(4):478-479.
13. Treatment of patients with nephrogenic systemic fibrosis with Glivec (NSF). Volume 2011: clinicaltrials.gov; 2009.
14. Prince M.R., Zhang H.L., Roditi G.H., Leiner T., Kucharczyk W. Risk factors for NSF: a literature review. J Magn Reson Imaging 2009, 30(6):1298-1308.
15. Hope T.A., High W.A., Leboit P.E., Chaopathomkul B., Rogut V.S., Herfkens R.J., et al. Nephrogenic systemic fibrosis in rats treated with erythropoietin and intravenous iron. Radiology 2009, 253(2):390-398.
16. Sieber M.A., Pietsch H., Walter J., Haider W., Frenzel T., Weinmann H.J. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol 2008, 43(1):65-75.
17. Swaminathan S., Ahmed I., McCarthy J.T., Albright R.C., Pittelkow M.R., Caplice N.M., et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med 2006, 145(3):234-235.
18. Swaminathan S., Horn T.D., Pellowski D., Abul-Ezz S., Bornhorst J.A., Viswamitra S., et al. Nephrogenic systemic fibrosis, gadolinium, and iron mobilization. N Engl J Med 2007, 357(7):720-722.
19. Muller Y.D., Mai G., Morel P., Serre-Beinier V., Gonelle-Gispert C., Yung G.P., et al. Anti-CD154 mAb and rapamycin induce T regulatory cell mediated tolerance in rat-to-mouse islet transplantation. PLoS One 2010, 5(4):e10352.
20. High W.A., Ayers R.A., Chandler J., Zito G., Cowper S.E. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007, 56(1):21-26.
21. Cowper S.E., Bucala R. Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. Am J Dermatopathol 2003, 25(4):358.
22. Pietsch H., Raschke M., Ellinger-Ziegelbauer H., Jost G., Walter J., Frenzel T., et al. The role of residual gadolinium in the induction of nephrogenic systemic fibrosis-like skin lesions in rats. Investigative Radiology 2011, 46(1):48-56.
23. Nazarian R.M., Mandal R.V., Kagan A., Kay J., Duncan L.M. Quantitative assessment of dermal cellularity in nephrogenic systemic fibrosis: a diagnostic aid. J Am Acad Dermatol 2011, 64(4):741-747.
24. Cowper S.E., Robin H.S., Steinberg S.M., Su L.D., Gupta S., LeBoit P.E. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000, 356(9234):1000-1001.
25. Ruiz-Genao D.P., Pascual-Lopez M.P., Fraga S., Aragues M., Garcia-Diez A. Osseous metaplasia in the setting of nephrogenic fibrosing dermopathy. J Cutan Pathol 2005, 32(2):172-175.
26. Wiedemeyer K., Kutzner H., Abraham J.L., Thakral C., Carlson J.A., Tran T.A., et al. The evolution of osseous metaplasia in localized cutaneous nephrogenic systemic fibrosis: a case report. Am J Dermatopathol 2009, 31(7):674-681.
27. Bhawan J., Swick B.L., Koff A.B., Stone M.S. Sclerotic bodies in nephrogenic systemic fibrosis: a new histopathologic finding. J Cutan Pathol 2009, 36(5):548-552.
28. Jan F., Segal J.M., Dyer J., LeBoit P., Siegfried E., Frieden I.J. Nephrogenic fibrosing dermopathy: two pediatric cases. J Pediatr 2003, 143(5):678-681.
29. Daniels C.E., Wilkes M.C., Edens M., Kottom T.J., Murphy S.J., Limper A.H., et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004, 114(9):1308-1316.